Bio-Rad launches COVID-19 antibody test kit

By staff writers

April 21, 2020 -- Bio-Rad Laboratories has begun shipping its SARS-CoV-2 Total Ab blood-based immunoassay kit.

The kit tests for immunoglobulin G, immunoglobulin M, and immunoglobulin A (IgG, IgM, and IgA) antibodies to SARS-CoV-2, the virus that causes COVID-19. In clinical evaluation, the SARS-CoV-2 Total Ab kit produced more than 99% diagnostic specificity and 98% diagnostic sensitivity, according to the firm. In addition, it yielded 100% specificity during cross-reactivity testing, showing no reactivity against other interfering specimens such as non-CoV-2 coronaviruses, Bio-Rad said.

The firm has applied for emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) and the company says that the test has also met the CE Mark requirement in Europe.

Biodesix, Bio-Rad file for emergency authorization of coronavirus test
Biodesix and Bio-Rad Laboratories have submitted an emergency use authorization application with the U.S. Food and Drug Administration for their Droplet...
Bio-Rad debuts guide to improve access to COVID-19 tests
Bio-Rad Laboratories has launched a standard for SARS-CoV-2 to help labs validate assays and speed up access to testing for COVID-19 novel coronavirus...
Bio-Rad taps new head of clinical diagnostics
Bio-Rad Laboratories has tapped diagnostics industry veteran Dara Grantham Wright as president of its Clinical Diagnostics Group, replacing John Hertia,...
Bio-Rad launches QX One PCR system at AMP 2019
Bio-Rad Laboratories announced the release of its QX One Droplet Digital polymerase chain reaction (ddPCR) system at the Association for Molecular Pathology...

Copyright © 2020

Last Updated ls 4/21/2020 1:27:19 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current